GP5 and breast carcinoma: In a trial comparing 2 aromatase inhibitors (ECOG-ACRIN E1Z03),11 researchers found that GP5 measured at baseline among postmenopausal women with receptor-positive primary breast cancer was associated with subsequent early treatment discontinuation.